CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Fenofibrate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01752842
NCT01752842N/ACompleted
CompareCT.gov

Lipid Biomarkers for Diabetic Heart Disease

Washington University School of Medicine·interventional·Posted Dec 19, 2012·Updated Mar 15, 2019

In Brief

A clinical study evaluating Fenofibrate and Placebo for fenofibrate for Type II Diabetes Mellitus and Diabetes Complications. Completed, enrolled 70 participants across 1 site.

Detailed Summary

This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus, Diabetes Complications
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Leducq Foundation

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 19, 2012
Enrollment StartMar 1, 2013
Primary CompletionFeb 23, 2018
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 13.5 years ago

Interventions

Fenofibratedrug

Placebo for fenofibratedrug